Wikipedia -WSS

Wikipedia

author：explore 2025-09-29 19:59:59 - browse：27

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Analysis of telehealth claims data suggest service duplication

WSS

Sana to lay off nearly a third of staff, de

Chemotherapy drug shortage eases slightly but still widespread

Pumping milk in bathrooms at health conferences is common

FDA panel signals lack of confidence in Amgen cancer drug data

Why age limits for politicians are a terrible idea

Mass General, Mayo Clinic look to monetize custom

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Supreme Court strikes down use of affirmative action

Analysis of telehealth claims data suggest service duplication

Activists slam private health insurers over coverage restrictions

A Q&A with the global head of Boehringer Ingelheim's innovation unit

In Memoriam: Notable people who died in 2023

Medicare drug price lawsuits could be good politics for Biden

Medical records are filled with copy

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Alkermes shareholders re

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

focus

Why age limits for politicians are a terrible idea

Chemotherapy drug shortage eases slightly but still widespread

Colorectal cancer study finds potential in overlooked immune cell

Medicare bonuses could stop drug shortages under Senate plan

What to expect at HLTH 2023, the health care industry conference

Histogen: Failed biotech offers rare public look inside

explore

focus

focus

leisure time